share_log

Earnings Call Summary | MYT Netherlands(MYTE.US) Q2 2024 Earnings Conference

moomoo AI ·  Feb 15 17:03  · Conference Call

The following is a summary of the MYT Netherlands Parent B.V. (MYTE) Q2 2024 Earnings Call Transcript:

Financial Performance:

  • MYT Netherlands reported an 8.3% growth in net sales and a 4% adjusted EBITDA margin.

  • The company's Growth Merchandise Value (GMV) increased by 5.9% at constant currency while the nominal GMV grew by 1.5% (€25.9 million in previous year to €219.1 million).

  • The company's operating cash flow was €19 million with €85 million in unused credit lines.

  • The second quarter saw net sales grow by 8.3% with an extraordinary 17.4% growth in the U.S market.

  • MYT Netherlands ended the quarter with a strong balance sheet indicated by 61% equity ratio.

Business Progress:

  • MYT Netherlands has shown resilience, achieving double-digit revenue growth in the U.S. and maintaining a gross profit margin of 50%.

  • This resilience, in conjunction with their inventory management strategy, puts them in a good position to achieve their target of 260 days inventory outstanding by the end of fiscal year '25.

  • Recent operational updates include expanding to a new Leipzig distribution centre, launching their own Apple Vision Pro app, and dropping exclusive collections with various luxury brands.

  • Looking forward, the company is well-positioned to capitalize on an anticipated expansion of the overall market and increasing online share in the luxury sector, as per the Bain-Altagamma research study.

More details: MYT Netherlands IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment